Cargando…
A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine
Kv1.2 channels, encoded by the KCNA2 gene, are localized in the central and peripheral nervous system, where they regulate neuronal excitability. Recently, heterozygous mutations in KCNA2 have been associated with a spectrum of symptoms extending from epileptic encephalopathy, intellectual disabilit...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469797/ https://www.ncbi.nlm.nih.gov/pubmed/34576077 http://dx.doi.org/10.3390/ijms22189913 |
_version_ | 1784574029483474944 |
---|---|
author | Imbrici, Paola Conte, Elena Blunck, Rikard Stregapede, Fabrizia Liantonio, Antonella Tosi, Michele D’Adamo, Maria Cristina De Luca, Annamaria Brankovic, Vesna Zanni, Ginevra |
author_facet | Imbrici, Paola Conte, Elena Blunck, Rikard Stregapede, Fabrizia Liantonio, Antonella Tosi, Michele D’Adamo, Maria Cristina De Luca, Annamaria Brankovic, Vesna Zanni, Ginevra |
author_sort | Imbrici, Paola |
collection | PubMed |
description | Kv1.2 channels, encoded by the KCNA2 gene, are localized in the central and peripheral nervous system, where they regulate neuronal excitability. Recently, heterozygous mutations in KCNA2 have been associated with a spectrum of symptoms extending from epileptic encephalopathy, intellectual disability, and cerebellar ataxia. Patients are treated with a combination of antiepileptic drugs and 4-aminopyridine (4-AP) has been recently trialed in specific cases. We identified a novel variant in KCNA2, E236K, in a Serbian proband with non-progressive congenital ataxia and early onset epilepsy, treated with sodium valproate. To ascertain the pathogenicity of E236K mutation and to verify its sensitivity to 4-AP, we transfected HEK 293 cells with Kv1.2 WT or E236K cDNAs and recorded potassium currents through the whole-cell patch-clamp. In silico analysis supported the electrophysiological data. E236K channels showed voltage-dependent activation shifted towards negative potentials and slower kinetics of deactivation and activation compared with Kv1.2 WT. Heteromeric Kv1.2 WT+E236K channels, resembling the condition of the heterozygous patient, confirmed a mixed gain- and loss-of-function (GoF/LoF) biophysical phenotype. 4-AP inhibited both Kv1.2 and E236K channels with similar potency. Homology modeling studies of mutant channels suggested a reduced interaction between the residue K236 in the S2 segment and the gating charges at S4. Overall, the biophysical phenotype of E236K channels correlates with the mild end of the clinical spectrum reported in patients with GoF/LoF defects. The response to 4-AP corroborates existing evidence that KCNA2-disorders could benefit from variant-tailored therapeutic approaches, based on functional studies. |
format | Online Article Text |
id | pubmed-8469797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84697972021-09-27 A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine Imbrici, Paola Conte, Elena Blunck, Rikard Stregapede, Fabrizia Liantonio, Antonella Tosi, Michele D’Adamo, Maria Cristina De Luca, Annamaria Brankovic, Vesna Zanni, Ginevra Int J Mol Sci Article Kv1.2 channels, encoded by the KCNA2 gene, are localized in the central and peripheral nervous system, where they regulate neuronal excitability. Recently, heterozygous mutations in KCNA2 have been associated with a spectrum of symptoms extending from epileptic encephalopathy, intellectual disability, and cerebellar ataxia. Patients are treated with a combination of antiepileptic drugs and 4-aminopyridine (4-AP) has been recently trialed in specific cases. We identified a novel variant in KCNA2, E236K, in a Serbian proband with non-progressive congenital ataxia and early onset epilepsy, treated with sodium valproate. To ascertain the pathogenicity of E236K mutation and to verify its sensitivity to 4-AP, we transfected HEK 293 cells with Kv1.2 WT or E236K cDNAs and recorded potassium currents through the whole-cell patch-clamp. In silico analysis supported the electrophysiological data. E236K channels showed voltage-dependent activation shifted towards negative potentials and slower kinetics of deactivation and activation compared with Kv1.2 WT. Heteromeric Kv1.2 WT+E236K channels, resembling the condition of the heterozygous patient, confirmed a mixed gain- and loss-of-function (GoF/LoF) biophysical phenotype. 4-AP inhibited both Kv1.2 and E236K channels with similar potency. Homology modeling studies of mutant channels suggested a reduced interaction between the residue K236 in the S2 segment and the gating charges at S4. Overall, the biophysical phenotype of E236K channels correlates with the mild end of the clinical spectrum reported in patients with GoF/LoF defects. The response to 4-AP corroborates existing evidence that KCNA2-disorders could benefit from variant-tailored therapeutic approaches, based on functional studies. MDPI 2021-09-14 /pmc/articles/PMC8469797/ /pubmed/34576077 http://dx.doi.org/10.3390/ijms22189913 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Imbrici, Paola Conte, Elena Blunck, Rikard Stregapede, Fabrizia Liantonio, Antonella Tosi, Michele D’Adamo, Maria Cristina De Luca, Annamaria Brankovic, Vesna Zanni, Ginevra A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine |
title | A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine |
title_full | A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine |
title_fullStr | A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine |
title_full_unstemmed | A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine |
title_short | A Novel KCNA2 Variant in a Patient with Non-Progressive Congenital Ataxia and Epilepsy: Functional Characterization and Sensitivity to 4-Aminopyridine |
title_sort | novel kcna2 variant in a patient with non-progressive congenital ataxia and epilepsy: functional characterization and sensitivity to 4-aminopyridine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469797/ https://www.ncbi.nlm.nih.gov/pubmed/34576077 http://dx.doi.org/10.3390/ijms22189913 |
work_keys_str_mv | AT imbricipaola anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT conteelena anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT blunckrikard anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT stregapedefabrizia anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT liantonioantonella anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT tosimichele anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT dadamomariacristina anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT delucaannamaria anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT brankovicvesna anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT zanniginevra anovelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT imbricipaola novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT conteelena novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT blunckrikard novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT stregapedefabrizia novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT liantonioantonella novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT tosimichele novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT dadamomariacristina novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT delucaannamaria novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT brankovicvesna novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine AT zanniginevra novelkcna2variantinapatientwithnonprogressivecongenitalataxiaandepilepsyfunctionalcharacterizationandsensitivityto4aminopyridine |